TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32238297

Group type: EXPERIMENTAL
Intervention: Tele‐BA (Behavioral Activation)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Tele‐FV (Friendly Visits)
Number of subjects: 89
Study: 35624347

Group type: EXPERIMENTAL
Intervention: Vericiguat added to standard of care (SOC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo added to standard of care (SOC)
Number of subjects: 0
Study: 36272026

Group type: EXPERIMENTAL
Intervention: SUBQ ravulizumab
Number of subjects: 136

Group type: COMPARATOR
Intervention: IV ravulizumab
Number of subjects: 136
Study: 33169203

Group type: COMPARATOR
Intervention: Oxycodone 5 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Oxycodone 10 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Alcohol (0.8 g/kg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Oxycodone + Alcohol
Number of subjects: 10
Study: 32345936

Group type: EXPERIMENTAL
Intervention: Multicenter trials in hand surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single-center studies
Number of subjects: 0
Study: 35667085

Group type: EXPERIMENTAL
Intervention: 1,300mg TXA orally or 1,000mg TXA intravenously thrice daily for maximum 30 days
Number of subjects: 337

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 337
Study: 33499902

Group type: EXPERIMENTAL
Intervention: Vegetarian target options
Number of subjects: 540

Group type: COMPARATOR
Intervention: Meat target options
Number of subjects: 540
Study: 32107929

Group type: EXPERIMENTAL
Intervention: FOLFIRI plus cetuximab
Number of subjects: 0

Group type: COMPARATOR
Intervention: FOLFIRI plus bevacizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab
Number of subjects: 0
Study: 33355200

Group type: EXPERIMENTAL
Intervention: Durvalumab + Tremelimumab
Number of subjects: 1001

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 1001
Study: 33975645

Group type: EXPERIMENTAL
Intervention: Online interdisciplinary intervention (10 weeks)
Number of subjects: 425

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 425
Study: 34226418

Group type: EXPERIMENTAL
Intervention: 1 mg atropine and 2 mg neostigmine
Number of subjects: 20

Group type: COMPARATOR
Intervention: 2 mg/kg sugammadex
Number of subjects: 20
Study: 35848152

Group type: EXPERIMENTAL
Intervention: Bidirectional pressurized porous tantalum screws (PTS)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Cannulated compression screws (CCS)
Number of subjects: 41
Study: 32816002

Group type: EXPERIMENTAL
Intervention: Anti-VEGF treatment, with varying fluctuations in retinal thickness (measured by FCPT SD).
Number of subjects: 1731
Study: 35148329

Group type: EXPERIMENTAL
Intervention: COTiD-UK (Community Occupational Therapy in Dementia-UK version)
Number of subjects: 468

Group type: COMPARATOR
Intervention: TAU (Treatment as Usual)
Number of subjects: 468
Study: 34214863

Group type: EXPERIMENTAL
Intervention: High self-disclosure questions
Number of subjects: 140

Group type: COMPARATOR
Intervention: Low self-disclosure questions
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: High self-disclosure
Number of subjects: 140

Group type: COMPARATOR
Intervention: Low self-disclosure
Number of subjects: 140
Study: 35901401

Group type: EXPERIMENTAL
Intervention: Mindfulness-based training (MBT)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Adaptive cognitive training (aCT)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Waitlist control (WL)
Number of subjects: 61
Study: 33559354

Group type: EXPERIMENTAL
Intervention: CT1812
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32289719

Group type: EXPERIMENTAL
Intervention: Active tDCS (bilateral primary motor cortex)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Active tDCS (supplementary motor area)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 60
Study: 35288021

Group type: EXPERIMENTAL
Intervention: HRT plus letrozole (2.5 mg oral letrozole twice daily for 5 days, with continuation of daily oestradiol)
Number of subjects: 112

Group type: COMPARATOR
Intervention: HRT only (daily intramuscular progesterone plus daily oestradiol)
Number of subjects: 112
Study: 32460396

Group type: EXPERIMENTAL
Intervention: Photobiomodulation (PBM) with a dose of 12 J/cm2 during 10 sessions
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo group (laser turned off)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Photobiomodulation (PBM)
Number of subjects: 20
Study: 34183568

Group type: EXPERIMENTAL
Intervention: Aerobic exercise intervention for 3 months
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control group (hospital routine care only)
Number of subjects: 98
Study: 32121236

Group type: EXPERIMENTAL
Intervention: Vitamin D (VID, 2000 IU/day)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Omega-3 long chain polyunsaturated fatty acids (OM, 722 mg/day docosahexaenoic acid)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Both Vitamin D and Omega-3 (VIDOM)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 34008442

Group type: EXPERIMENTAL
Intervention: Patch pump
Number of subjects: 278

Group type: COMPARATOR
Intervention: Insulin pen
Number of subjects: 278
Study: 33706870

Group type: EXPERIMENTAL
Intervention: Intensive systolic blood pressure treatment (<120 mm Hg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard systolic blood pressure treatment (<140 mm Hg)
Number of subjects: 0
Study: 32151822

Group type: EXPERIMENTAL
Intervention: Long DAPT (12-24 months) in HBR patients
Number of subjects: 10081

Group type: COMPARATOR
Intervention: Short DAPT (3-6 months) in HBR patients
Number of subjects: 10081

Group type: EXPERIMENTAL
Intervention: Long DAPT (12-24 months) in non-HBR patients
Number of subjects: 10081

Group type: COMPARATOR
Intervention: Short DAPT (3-6 months) in non-HBR patients
Number of subjects: 10081
Study: 34145538

Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula (HFNC)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Continuous positive airway pressure (CPAP)
Number of subjects: 28
Study: 32693116

Group type: EXPERIMENTAL
Intervention: Rhubarb navel plasters (Rheum officinale rhubarb powder)
Number of subjects: 374

Group type: COMPARATOR
Intervention: Placebo flour stick
Number of subjects: 374
Study: 36300825

Group type: EXPERIMENTAL
Intervention: Photodynamic diagnosis-guided transurethral resection of bladder tumour
Number of subjects: 538

Group type: COMPARATOR
Intervention: White-light-guided transurethral resection of bladder tumour
Number of subjects: 538
Study: 34289428

Group type: EXPERIMENTAL
Intervention: Chai Hu oral liquid high dosage
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Chai Hu oral liquid middle dosage
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Chai Hu oral liquid low dosage
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Jieshu KangreSan (Positive control)
Number of subjects: 480

Group type: COMPARATOR
Intervention: PBS (Control group)
Number of subjects: 480
Study: 32398326

Group type: EXPERIMENTAL
Intervention: Cardiopulmonary irradiation (specific doses not detailed)
Number of subjects: 437
Study: 35647186

Group type: EXPERIMENTAL
Intervention: Nicorandil tablets
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group (asprin)
Number of subjects: 104
Study: 33784983

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided parasternal intercostal nerve block with ropivacaine
Number of subjects: 41

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 41
Study: 32541498

Group type: EXPERIMENTAL
Intervention: Topical tranexamic acid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous tranexamic acid
Number of subjects: 0
Study: 35216555

Group type: EXPERIMENTAL
Intervention: CFI-enhanced diagnostic procedure (n=134)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Routine diagnostic procedures (Control group, n=122)
Number of subjects: 256
Study: 34044869

Group type: EXPERIMENTAL
Intervention: Sequential implementation strategy (first centered on nurses, then involving physicians)
Number of subjects: 3273

Group type: COMPARATOR
Intervention: Global implementation strategy (promoting cooperation of all health professionals from the beginning)
Number of subjects: 3273

Group type: EXPERIMENTAL
Intervention: Prescription of lifestyle change
Number of subjects: 3273
Study: 35282830

Group type: EXPERIMENTAL
Intervention: Inconsistent responding screening during data collection
Number of subjects: 626

Group type: COMPARATOR
Intervention: Participants screened in to the RCT
Number of subjects: 626
Study: 35297768

Group type: EXPERIMENTAL
Intervention: Mobile health intervention delivered via an existing service communication app for 10 weeks, including weekly push notifications and resources.
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: Mobile health intervention (per-protocol analysis including only parents who downloaded the app).
Number of subjects: 355

Group type: COMPARATOR
Intervention: N/A (Control group did not receive any intervention).
Number of subjects: 355
Study: 32352803

Group type: EXPERIMENTAL
Intervention: I-PCIT (5 days/week over 2 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Time-limited PCIT (1 day/week over 10 weeks)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: I-PCIT
Number of subjects: 60
Study: 35466050

Group type: EXPERIMENTAL
Intervention: Diltiazem (up to 360 mg/d)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study: 34195864

Group type: EXPERIMENTAL
Intervention: ThrIVe-B intervention plus treatment as usual
Number of subjects: 43

Group type: COMPARATOR
Intervention: Treatment as usual (control arm)
Number of subjects: 43
Study: 35253279

Group type: EXPERIMENTAL
Intervention: Milk protein
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Blends of milk and rapeseed protein (ratio 54:46 or 30:70)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 88
Study: 32609001

Group type: EXPERIMENTAL
Intervention: Extraverted presentation in public virtual environments
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Introverted presentation in public virtual environments
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Extraverted presentation in private virtual environments
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Introverted presentation in private virtual environments
Number of subjects: 0
Study: 36006772

Group type: EXPERIMENTAL
Intervention: CT-P63
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 33469713

Group type: EXPERIMENTAL
Intervention: Home phototherapy
Number of subjects: 147

Group type: COMPARATOR
Intervention: Conventional in-hospital phototherapy
Number of subjects: 147
Study: 35063267

Group type: EXPERIMENTAL
Intervention: telmisartan 40 mg/day + amlodipine 5 mg/day
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: telmisartan 40 mg/day + cilnidipine 10 mg/day
Number of subjects: 94
Study: 34807655

Group type: EXPERIMENTAL
Intervention: Single-sex groups with food response inhibition and attention training
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Mixed-sex groups with food response inhibition and attention training
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Single-sex groups with generic response inhibition and attention training
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Mixed-sex groups with generic response inhibition and attention training
Number of subjects: 261
Study: 32729404

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (alpha2-agonist)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Yohimbine (alpha2-antagonist)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 35969194

Group type: EXPERIMENTAL
Intervention: Isometric exercise training (IET) - wall squat, 3 times per week for 1 year
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group - nonintervention
Number of subjects: 24
Study: 33118429

Group type: EXPERIMENTAL
Intervention: Spirulina (5.7 g/d)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (isoproteic and caloric)
Number of subjects: 22
Study: 32839253

Group type: COMPARATOR
Intervention: LIA with CACB
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: iPACK block with LIA and CACB
Number of subjects: 72
Study: 36085237

Group type: EXPERIMENTAL
Intervention: Combined 2×/week aerobic training (AT) + 2×/week resistance training (RT)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: 2×/week AT + 2×/week active control (balance and tone, BAT)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: 2×/week RT + 2×/week active control (BAT)
Number of subjects: 216

Group type: COMPARATOR
Intervention: 4×/week active control (BAT)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: All groups will also be assessed for secondary outcomes including health-related quality of life, physical function, actigraphy measures, questionnaires, and falls.
Number of subjects: 216
Study: 32211958

Group type: EXPERIMENTAL
Intervention: Penta E locus
Number of subjects: 571

Group type: EXPERIMENTAL
Intervention: TPOX locus
Number of subjects: 571

Group type: EXPERIMENTAL
Intervention: Observed heterozygosity
Number of subjects: 571

Group type: EXPERIMENTAL
Intervention: Power of discrimination (PD)
Number of subjects: 571

Group type: EXPERIMENTAL
Intervention: Power of exclusion (PE)
Number of subjects: 571

Group type: EXPERIMENTAL
Intervention: Matching probability (PM)
Number of subjects: 571

Group type: EXPERIMENTAL
Intervention: Paternity index (PI)
Number of subjects: 571
Study: 33599993

Group type: EXPERIMENTAL
Intervention: High-flow nasal oxygen (100% oxygen)
Number of subjects: 350

Group type: COMPARATOR
Intervention: Tight-fitting facemask
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: High-flow nasal oxygen
Number of subjects: 350
Study: 33153313

Group type: EXPERIMENTAL
Intervention: Remote symptom monitoring intervention, delivered during daily automated coaching
Number of subjects: 358

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 358
Study: 35025558

Group type: EXPERIMENTAL
Intervention: COPE (Concurrent Treatment of PTSD and SUD Using Prolonged Exposure)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Relapse Prevention (RP) therapy for SUD
Number of subjects: 81
Study: 35538430

Group type: EXPERIMENTAL
Intervention: 6 months health coaching, sit-stand desktop workstation, activity tracker (Fitbit), followed by 6 months text message support, then 6 months maintenance.
Number of subjects: 250

Group type: COMPARATOR
Intervention: Delayed modified intervention after 12 months of usual care.
Number of subjects: 250
Study: 33712987

Group type: EXPERIMENTAL
Intervention: Apremilast (30 mg twice daily)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Methotrexate (0.4 mg/kg/week orally)
Number of subjects: 84
Study: 34802925

Group type: EXPERIMENTAL
Intervention: Intranasal administration of dexmedetomidine (0.1 mg kg–1) with midazolam (2 mg kg–1)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Intramuscular administration of dexmedetomidine (0.1 mg kg–1) with midazolam (2 mg kg–1)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Intranasal administration
Number of subjects: 8

Group type: COMPARATOR
Intervention: Intramuscular administration
Number of subjects: 8

Group type: COMPARATOR
Intervention: Both treatments (IN and IM)
Number of subjects: 8
Study: 33260183

Group type: EXPERIMENTAL
Intervention: Oxycodone combined with propofol (group OP)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Fentanyl combined with propofol (group FP)
Number of subjects: 193
Study: 35301878

Group type: EXPERIMENTAL
Intervention: UC + single general ward rehabilitation (SGR group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: UC + general ward rehabilitation and intensive care unit (ICU) rehabilitation (IGR group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (UC group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 0
Study: 32110805

Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Aggressive tumor resection
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Extent of resection
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Surgery + Radiotherapy
Number of subjects: 211

Group type: COMPARATOR
Intervention: Surgery without Radiotherapy
Number of subjects: 211
Study: 36136791

Group type: EXPERIMENTAL
Intervention: Enhanced incentive (EI) condition, financial bonus based on performance improvement
Number of subjects: 38

Group type: COMPARATOR
Intervention: Standard incentive (SI) condition, chance-based bonus
Number of subjects: 38
Study: 34264835

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) group
Number of subjects: 347

Group type: COMPARATOR
Intervention: Antidepressant Treatment (AT) group
Number of subjects: 347
Study: 35951209

Group type: EXPERIMENTAL
Intervention: PC-CARE intervention
Number of subjects: 49

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 49
Study: 33879852

Group type: EXPERIMENTAL
Intervention: Positive psychology intervention (PPI), eight-session, telephone-delivered, completed by 12 participants (60% of those who started the intervention)
Number of subjects: 45
Study: 32331886

Group type: EXPERIMENTAL
Intervention: Fish meal (FM)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Blood meal (BM)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (0% FM/BM)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Increasing levels of FM or BM (33%, 67%, 100%)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Overall treatment (FM and BM)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Individual AA (Arginine, Ile, Met, Phe, His)
Number of subjects: 8
Study: 35867199

Group type: EXPERIMENTAL
Intervention: Imeglimin (250–8000 mg single dose; 250–2000 mg twice daily multiple doses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34818391

Group type: EXPERIMENTAL
Intervention: Modified lip repositioning technique with periosteal sutures
Number of subjects: 12

Group type: COMPARATOR
Intervention: Original LipStaT technique (Control)
Number of subjects: 12
Study: 36193713

Group type: EXPERIMENTAL
Intervention: Liraglutide 3 mg administered subcutaneously daily
Number of subjects: 136

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Liraglutide 3 mg
Number of subjects: 136
Study: 34451039

Group type: EXPERIMENTAL
Intervention: Sensor-based gait retraining
Number of subjects: 71

Group type: COMPARATOR
Intervention: Walking exercise
Number of subjects: 71
Study: 32302682

Group type: EXPERIMENTAL
Intervention: Postoperative tangential whole breast radiation therapy (RT)
Number of subjects: 1187

Group type: COMPARATOR
Intervention: No further treatment (Control group)
Number of subjects: 1187
Study: 35048156

Group type: EXPERIMENTAL
Intervention: Progressive Resistance Training (PRT)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Non-PRT
Number of subjects: 109
Study: 32784412

Group type: EXPERIMENTAL
Intervention: High-gamma-polyglutamic acid (HPGA) natto (439.6 mg of γ-PGA)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Low-gamma-polyglutamic acid (LPGA) natto (57.6 mg of γ-PGA)
Number of subjects: 36
Study: 35555447

Group type: EXPERIMENTAL
Intervention: Virtual Reality (Oculus Quest 2TM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AlioscopyTM
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Physical 3D-printed bone model
Number of subjects: 0
Study: 32293798

Group type: EXPERIMENTAL
Intervention: Temsirolimus 115 mg weekly and perifosine 100 mg daily (following 600 mg load)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Temsirolimus 50 mg (dose level 3)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Temsirolimus 170 mg (dose level 7)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Temsirolimus 170 mg (dose level 6)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Temsirolimus (various doses)
Number of subjects: 35
Study: 32268867

Group type: EXPERIMENTAL
Intervention: Insulin U‐500
Number of subjects: 0
Study: 36152381

Group type: EXPERIMENTAL
Intervention: Estratetraenol
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control carrier
Number of subjects: 76
Study: 33733339

Group type: EXPERIMENTAL
Intervention: Stearic acid-rich meals
Number of subjects: 32

Group type: COMPARATOR
Intervention: Palmitic acid-rich meals
Number of subjects: 32
Study: 32147078

Group type: EXPERIMENTAL
Intervention: 600 IU alpha-tocopherol soft gels (200 IU three times daily)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo soft gels
Number of subjects: 49
Study: 36364888

Group type: EXPERIMENTAL
Intervention: Tritordeum-Based Diet (TBD)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Low-FODMAPs Diet (LFD)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Both TBD and LFD
Number of subjects: 38
Study: 33768237

Group type: EXPERIMENTAL
Intervention: Secnidazole 2 g single oral dose
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 36281743

Group type: EXPERIMENTAL
Intervention: Mindfulness training
Number of subjects: 43

Group type: COMPARATOR
Intervention: Relaxation training
Number of subjects: 43
Study: 32960456

Group type: EXPERIMENTAL
Intervention: Management toolkit
Number of subjects: 131

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 131
Study: 35820337

Group type: EXPERIMENTAL
Intervention: Gamers asked about their playing habits prior to the study
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Non-gamers asked about their playing habits prior to the study
Number of subjects: 121

Group type: COMPARATOR
Intervention: Gamers asked about their playing habits following the study
Number of subjects: 121

Group type: COMPARATOR
Intervention: Non-gamers asked about their playing habits following the study
Number of subjects: 121
Study: 33772502

Group type: EXPERIMENTAL
Intervention: Experimental day exercise (after maximal incremental test)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control (non-exercise)
Number of subjects: 39
Study: 32935529

Group type: EXPERIMENTAL
Intervention: GLB plus nutrigenomics
Number of subjects: 140

Group type: COMPARATOR
Intervention: Standard GLB program
Number of subjects: 140
Study: 35246585

Group type: EXPERIMENTAL
Intervention: HR+/HER2+ subtype patients
Number of subjects: 4310

Group type: EXPERIMENTAL
Intervention: HR-/HER2- subtype patients
Number of subjects: 4310
Study: 35493455

Group type: EXPERIMENTAL
Intervention: mepolizumab 300 mg subcutaneously every 4 weeks for 32 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: mepolizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0